Dermatomyositis Clinical Trials

39 recruitingLast updated: June 18, 2026

There are 39 actively recruiting dermatomyositis clinical trials across 35 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable. Top locations include Bethesda, Maryland, United States, Pittsburgh, Pennsylvania, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Dermatomyositis Trials at a Glance

39 actively recruiting trials for dermatomyositis are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Bethesda, Pittsburgh, and Houston. Lead sponsors running dermatomyositis studies include Chongqing Precision Biotech Co., Ltd, National Institute of Environmental Health Sciences (NIEHS), and Assistance Publique - Hôpitaux de Paris.

Browse dermatomyositis trials by phase

Treatments under study

About Dermatomyositis Clinical Trials

Looking for clinical trials for Dermatomyositis? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dermatomyositis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dermatomyositis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting

Adult and Juvenile Myositis

DermatomyositisInclusion Body MyositisPolymyositis
National Institute of Environmental Health Sciences (NIEHS)1,200 enrolled4 locationsNCT00017914
Recruiting

Environmental Risk Factors for the Anti-synthetase Syndrome

DermatomyositisPolymyositisMyositis+2 more
National Institute of Environmental Health Sciences (NIEHS)580 enrolled8 locationsNCT01276470
Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis

Autoinflammatory DiseaseJuvenile Dermatomyositis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000 enrolled1 locationNCT00059748
Recruiting
Phase 3

Baricitinib in Patients With Relapsing or naïve Dermatomyositis

Dermatomyositis
Assistance Publique - Hôpitaux de Paris62 enrolled1 locationNCT04972760
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Polymyositis, Dermatomyositis
AstraZeneca240 enrolled236 locationsNCT06455449
Recruiting
Phase 3

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

DermatomyositisPolymyositis
Pfizer211 enrolled24 locationsNCT06698796
Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822
Recruiting
Phase 2Phase 3

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS
Restem, LLC.40 enrolled2 locationsNCT07160205
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting
Phase 1Phase 2

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Juvenile Myasthenia GravisANCA Associated Vasculitis (AAV)Juvenile Dermatomyositis+1 more
Cartesian Therapeutics50 enrolled2 locationsNCT07089121
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting

Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

Dermatomyositis
University of Pennsylvania300 enrolled1 locationNCT02945345
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188
Recruiting
Not Applicable

RCT of Tocilizumab for Anti-MDA5+DM

Dermatomyositis
Peking Union Medical College Hospital110 enrolled1 locationNCT07377058
Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

DermatomyositisInflammatory MyopathyInclusion Body Myositis+9 more
Myositis International Health & Research Collaborative Alliance Foundation700 enrolled1 locationNCT07374107